tirzepatide patent expiry expiration eli lilly Tirzepatide's primary patents expire in 2036 but Eli Lilly has already secured additional patents that could extend its monopoly five more years Republican Administration Maintains Exclusivity Stance

This is not a well-characterized risk, but it is a physiologically plausible one that warrants discussion with a provider

As of early 2026, market research data from IQVIA indicates that GLP-1 receptor agonist prescriptions in the United States are growing at approximately 35% year-over-year, with an estimated 9 million active patients on GLP-1 therapies, a figure projected to exceed 30 million by 2030

Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ (2004) Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1

Colace Generic Alternatives: For gentle relief from constipation with a stool softener